Pages

Monday, March 7, 2016

MARIA SHARAPOVA DOPING: WHAT IS MELDONIUM?


Maria Sharapova has only played three tournaments in the last eight months after being plagued with injury
Meldonium was a medicine Sharapova took for 10 years but it became a prohibited substance on January 1
Maria Sharapova has only played three tournaments in the last eight months after being plagued with injury
Maria Sharapova has only played three tournaments in the last eight months after being plagued with injury
Speculation was rife that 2004 Wimbledon champion (pictured with her trophy) would hang up her racket prior to Monday's announcement
Speculation was rife that 2004 Wimbledon champion (pictured with her trophy) would hang up her racket prior to Monday's announcement
She falls to her knees in celebration after beating Serena Williams in 2004 final
The Russian poses with her Wimbledon trophy in 2004
She falls to her knees in celebration (left) and poses with trophy after beating Serena Williams in 2004 final

WHAT IS MELDONIUM?

Meldonium, also known as Mildronate, was added to the new banned list of drugs last year, which came into place on January 1, 2016.
The drug was added to the list because the World Doping Anti-Agency said there 'evidence of its use by athletes with the intention of enhancing performance.'
WADA had been observing Meldonium in 2015, adding it to its 'monitoring programme' to determine its effects on athletic performance.
It is used medically to treat ischemia, or a lack of blood flow. It can be used as a metabolic enhancer to increase endurance through greater blood flow.
The Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne said of the drug: 'Anti-ischemic drug Mildronate demonstrates an increase in endurance performance of athletes, improved rehabilitation after exercise, protection against stress, and enhanced activations of central nervous system (CNS) functions.' 
Sharapova said she has been taking the drug since 2006 to aid in a variety of health problems.
On December 22 of last year, WADA sent out an email indicating what drugs would be banned starting in 2016 and Sharapova conceded that she received but did not read that email. 
'I failed the test and take full responsibility for that. I had been taking this medicine for the past 10 years, but on 1 January this became a prohibited substance which I did not know.' 
Sharapova, who has played in only one tournament this year, losing to Serena Williams in the quarter-finals of the Australian Open, said she received a letter from the ITF informing her of the failed test for Meldonium.
Meldonium, also known as Mildronate, was added to the new banned list of drugs last year, which came into place on January 1, 2016.
The drug was added to the list because the World Doping Anti-Agency said there 'evidence of its use by athletes with the intention of enhancing performance.'
WADA had been observing Meldonium in 2015, adding it to its 'monitoring programme' to determine its effects on athletic performance.
It is used medically to treat ischemia, or a lack of blood flow. It can be used as a metabolic enhancer to increase endurance through greater blood flow.
The Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne said of the drug: 'Anti-ischemic drug Mildronate demonstrates an increase in endurance performance of athletes, improved rehabilitation after exercise, protection against stress, and enhanced activations of central nervous system (CNS) functions.'  
Sharapova has played only three tournaments in the past eight months and recently has had a succession of problems with her right arm and shoulder, the latter having already undergone surgery in 2013. 


MARIA SHARAPOVA DOPING: WHAT IS MELDONIUM?
Meldonium, also known as Mildronate, was added to the new banned list of drugs last year, which came into place on January 1, 2016.
The drug was added to the list because the World Doping Anti-Agency said there 'evidence of its use by athletes with the intention of enhancing performance.'
WADA had been observing Meldonium in 2015, adding it to its 'monitoring programme' to determine its effects on athletic performance.
It is used medically to treat ischemia, or a lack of blood flow. It can be used as a metabolic enhancer to increase endurance through greater blood flow.
The Institute of Biochemistry - Center for Preventive Doping Research, German Sport University Cologne said of the drug: 'Anti-ischemic drug Mildronate demonstrates an increase in endurance performance of athletes, improved rehabilitation after exercise, protection against stress, and enhanced activations of central nervous system (CNS) functions.' 
Sharapova said she has been taking the drug since 2006 to aid in a variety of health problems.
On December 22 of last year, WADA sent out an email indicating what drugs would be banned starting in 2016 and Sharapova conceded that she received but did not read that email. 

No comments:

Post a Comment